Pfizer Inc.’s COVID-19 vaccine was 73.2% effective against the disease in a trial of children 6 months through 4 years old, reinforcing results that led to the shot’s authorization in young kids in June.
The three-dose regimen was compared with placebo injections during the period when omicron’s BA.2 version was spreading widely from March to June, Pfizer and partner BioNTech SE said Tuesday in a statement. There were 13 cases in the vaccinated group and 21 in the placebo group, the statement said.
Pfizer and BioNTech’s messenger RNA vaccine was authorized for use in young children based on results that showed it generated a similar immune response to one that was seen as protective in adults. When regulators authorized the shots, they said that Pfizer's effectiveness data in young children were not yet mature.
